Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mibefradil

Drug Profile

Mibefradil

Alternative Names: Batenac®; Befral®; Cerate®; Mibefradil dihydrochloride; Posicor®; Quota®; RO 40-5967; Taxben®

Latest Information Update: 14 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Cavion
  • Class Antihypertensives; Benzimidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrahydronaphthalenes; Vasodilators
  • Mechanism of Action Cell division modulators; DNA repair inhibitors; T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Ovarian cancer; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Angina pectoris; Hypertension
  • No development reported Glioblastoma; Glioma; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Discontinued Arrhythmias; Heart failure

Most Recent Events

  • 12 Aug 2019 Cavion has been acquired by Jazz Pharmaceuticals plc
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Recurrent, Second-line therapy or greater) in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Recurrent, Second-line therapy or greater) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top